Total debt has stabilized near $35.6M while the debt-to-equity ratio fell from 1.33 to 0.13 and cash rose to $119.7M with a current ratio of 1.65, pointing to a strengthened capital structure built largely through retained earnings.
Guardian Pharmacy Services, Inc. (GRDN) balance sheet — 8-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Total Current Assets | 294.82M | 221.63M | 151.99M | 129.6M | 120M | 111.87M | 93.82M | 90.08M | 81.23M |
| Cash & Short-Term Investments | 119.66M | 65.62M | 4.66M | 752K | 607K | 15.01M | 6.45M | 275K | 2.25M |
| Cash Only | 119.66M | 65.62M | 4.66M | 752K | 607K | 15.01M | 6.45M | 275K | 2.25M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 107.68M | 101.61M | 97.15M | 77.26M | 67.83M | 55.25M | 45.78M | 54.21M | 47.66M |
| Days Sales Outstanding | 26.6 | 25.6 | 28.87 | 26.96 | 27.24 | 25.46 | 22.7 | 28.34 | 28.97 |
| Inventory | 57.05M | 43.36M | 40.55M | 36.73M | 41.44M | 33.09M | 31.93M | 30.94M | 27.54M |
| Days Inventory Outstanding | 15.99 | 13.57 | 15.04 | 16 | 20.92 | 19.15 | 19.79 | 20.35 | 21.06 |
| Other Current Assets | 10.43M | 11.04M | 9.62M | 14.86M | 10.12M | 8.52M | 2.89M | 4.66M | 3.78M |
| Total Non-Current Assets | 196.96M | 191.02M | 168.82M | 141.56M | 136.12M | 123.98M | 124.05M | 106.43M | 100.58M |
| Property, Plant & Equipment | 90.2M | 90.17M | 78.96M | 73.18M | 65.19M | 51.72M | 51.98M | 35.41M | 27.98M |
| Fixed Asset Turnover | 16.18x | 16.07x | 15.56x | 14.30x | 13.94x | 15.31x | 14.16x | 19.72x | 21.46x |
| Goodwill | 81.95M | 79.74M | 69.3M | 56.05M | 56.05M | 54.63M | 52.45M | 46.33M | 47.82M |
| Intangible Assets | 20.84M | 18.48M | 14.91M | 11.98M | 14.44M | 17.09M | 19.11M | 20.69M | 23.82M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1.35M | 436K | 383K | 358K | 435K | 529K | 505K | 4.01M | 953K |
| Total Assets | 491.78M | 412.66M | 320.81M | 271.17M | 256.11M | 235.85M | 217.87M | 196.51M | 181.81M |
| Asset Turnover | 3.28x | 3.51x | 3.83x | 3.86x | 3.55x | 3.36x | 3.38x | 3.55x | 3.30x |
| Asset Growth % | 107.03% | 28.63% | 18.31% | 5.88% | 8.59% | 8.25% | 10.87% | 8.09% | - |
| Total Current Liabilities | 179.09M | 160.7M | 144.12M | 138.01M | 112M | 111.54M | 86.35M | 90.19M | 65.27M |
| Accounts Payable | 126.31M | 116.21M | 102.42M | 85.6M | 78.1M | 64.62M | 53.41M | 54.93M | 47.53M |
| Days Payables Outstanding | 37.09 | 36.36 | 37.99 | 37.29 | 39.43 | 37.39 | 33.1 | 36.14 | 36.34 |
| Short-Term Debt | 0 | 0 | 0 | 12.98M | 7.96M | 3.71M | 3.63M | 17.04M | 2.64M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 25.28M | 37.35M | 34.87M | 12.33M | 3.62M | 20.42M | 0 | 9.94M | 7.68M |
| Current Ratio | 1.65x | 1.38x | 1.05x | 0.94x | 1.07x | 1.00x | 1.09x | 1.00x | 1.24x |
| Quick Ratio | 1.33x | 1.11x | 0.77x | 0.67x | 0.70x | 0.71x | 0.72x | 0.66x | 0.82x |
| Cash Conversion Cycle | 5.5 | 2.81 | 5.92 | 5.66 | 8.73 | 7.21 | 9.39 | 12.55 | 13.69 |
| Total Non-Current Liabilities | 32.97M | 34.03M | 26.71M | 73.29M | 68.18M | 70.99M | 64.44M | 49.28M | 48.53M |
| Long-Term Debt | 0 | 0 | 0 | 18.99M | 22.97M | 26.99M | 30.74M | 33.66M | 36.37M |
| Capital Lease Obligations | 115.48M | 29.99M | 23.3M | 27.04M | 23.67M | 16.12M | 15.54M | 3.59M | 2.35M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 5M | 4.04M | 3.42M | 27.26M | 21.54M | 27.88M | 18.16M | 12.03M | 9.81M |
| Total Liabilities | 212.06M | 194.73M | 170.83M | 211.31M | 180.18M | 182.53M | 150.8M | 139.47M | 113.8M |
| Total Debt | 35.59M | 37.14M | 30.13M | 69.15M | 62.98M | 55.04M | 58.84M | 57.12M | 43.71M |
| Net Debt | -84.06M | -28.48M | 25.47M | 68.4M | 62.38M | 40.03M | 52.39M | 56.84M | 41.46M |
| Debt / Equity | 0.13x | 0.17x | 0.20x | 1.16x | 0.83x | 1.03x | 0.88x | 2.06x | 0.64x |
| Debt / EBITDA | 0.29x | 0.33x | - | 1.17x | 0.92x | 1.18x | 1.19x | 1.14x | 1.12x |
| Net Debt / EBITDA | -0.68x | -0.26x | - | 1.16x | 0.91x | 0.86x | 1.06x | 1.14x | 1.06x |
| Interest Coverage | 163.29x | 111.41x | -19.28x | 14.19x | 26.78x | 18.30x | 14.76x | 14.94x | 13.25x |
| Total Equity | 279.72M | 217.92M | 149.98M | 59.86M | 75.93M | 53.32M | 67.07M | 27.72M | 68.01M |
| Equity Growth % | 174.19% | 45.31% | 150.55% | -21.16% | 42.41% | -20.5% | 141.97% | -59.24% | - |
| Book Value per Share | 4.38 | 3.44 | 2.42 | 0.98 | 1.25 | 0.88 | 1.10 | 0.46 | 1.12 |
| Total Shareholders' Equity | 267.24M | 205.76M | 142.67M | 28.21M | 42.73M | 23.93M | 38.48M | 0 | 34.03M |
| Common Stock | 63K | 63K | 63K | 28.21M | 42.73M | 24.11M | 39.15M | 29.95M | 34.03M |
| Retained Earnings | 120.19M | 66.34M | 17.12M | 0 | 0 | 0 | 0 | 0 | 0 |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | -185K | -676K | -630K | -386K |
| Minority Interest | 12.48M | 12.16M | 7.3M | 31.65M | 33.2M | 29.39M | 28.59M | 27.72M | 25.86M |
Quick answers to the most common questions about buying GRDN stock.
As of 2025, Guardian Pharmacy Services, Inc. (GRDN) had total assets of $412.7M including $221.6M in current assets.
Guardian Pharmacy Services, Inc. (GRDN) carries total debt of $37.1M, offset by $65.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Guardian Pharmacy Services, Inc. (GRDN) has total shareholders' equity (book value) of $205.8M ($3.44 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Guardian Pharmacy Services, Inc. (GRDN) reported a current ratio of 1.38x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Thin margins amid pricing pressure
Metrics are mathematically derived from official filings.
Equity Base Rebuilt Through Retained Earnings
Based on reported balance sheet figures, GRDN's equity rose from $17.9M in Q2 2024 to $267.2M in Q3 2026, with retained earnings climbing from zero to $120.2M, indicating a balance sheet strengthening through internal profit generation rather than external capital.
The transition from a near-zero equity base to a $267.2M position within roughly two years suggests the earnings base has been retained rather than distributed in recent periods. Total assets growing from $305.1M to $491.8M alongside a sharp rise in cash to $119.7M points to a company that is accumulating liquidity. This pattern warrants monitoring for whether retained cash is deployed productively into acquisitions or organic growth, given that the recent EPS miss may slow the pace of retained earnings accumulation.
Leverage Reduced to Minimal Levels
According to reported figures, GRDN's debt-to-equity ratio fell from 1.33 in Q2 2024 to 0.13 in Q3 2026, with total debt stabilizing near $35.6M, suggesting a deliberate deleveraging rather than a refinancing-driven improvement.
Total debt has held in a narrow $33.7M to $37.1M range since early 2025 while equity expanded, which mechanically compressed the leverage ratio. The earlier debt spike to roughly $76.0M appears to have been retired or restructured, though the reported data does not disclose the specific repayment mechanism. Low leverage preserves financial flexibility for acquisitions and absorbs margin shocks, though the reported figures do not indicate the terms, maturity profile, or covenants attached to the remaining obligations.
Cash Buffer Strengthening Against Working Capital Swings
As reported in financial statements, GRDN's cash rose from $4.7M in Q4 2024 to $119.7M in Q3 2026, while the current ratio improved from 1.05 to 1.65, indicating a meaningfully larger buffer against working capital volatility.
The current ratio of 1.65 and cash of $119.7M provide a substantive cushion relative to a business with a 19.5% gross margin and quarterly operating income near $25M. Given that prior cash flow analysis showed working capital swings of roughly $16M in either direction, this liquidity position appears adequate to absorb a single adverse quarter. The cash build appears partly driven by operating cash generation, though the sustainability of this buffer depends on whether working capital reversals recur.
Asset-Light Model With Growing Goodwill Exposure
Reported figures show goodwill increasing from $66.4M to $82.0M and net PP&E holding near $90M, suggesting an asset base that is increasingly weighted toward acquired intangibles rather than physical capital.
Goodwill now represents a meaningful share of total assets of $491.8M, and its growth tracks the bolt-on acquisition activity noted in prior cash flow findings. Net PP&E at roughly $90M relative to a business of this revenue scale is consistent with a capital-light pharmacy services model. If acquired contracts underperform, goodwill impairment could erode equity, though the reported data does not indicate any impairment charges or testing outcomes.
Cash Build Masks Thin Earnings Cushion
Based on reported figures, the rise in cash to $119.7M coincides with a net margin of 5.0% and an operating margin of 6.8%, so the apparent strength of the balance sheet may be more dependent on working capital timing than on sustained earnings power.
A strong cash position paired with thin profitability can overstate financial resilience if a portion of the cash build reflects timing of payables or receivables rather than durable earnings. The Q3 2026 EPS shortfall against consensus reinforces the possibility that margin pressure could erode retained earnings growth faster than the balance sheet currently reflects. Investors should monitor whether future cash accumulation tracks net income or diverges from it.